N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment

被引:10
|
作者
Shi, Yanlong [1 ]
Wang, Yizhu [1 ]
Zhang, Wenning [1 ]
Niu, Kaiyi [1 ]
Mao, Xinyu [1 ]
Feng, Kun [1 ]
Zhang, Yewei [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 2, Hepatopancreatobiliary Ctr, Nanjing, Jiangsu, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
N6-methyladenosine; hnRNPC; PD-L1; hepatocellular carcinoma; prognosis; immune infiltration; immunotherapy; RNA; M(6)A; TRANSCRIPTOME; ROLES;
D O I
10.3389/fendo.2023.1153802
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundIncreasing evidence elucidated N6-methyladenosine (m6A) dysregulation participated in regulating RNA maturation, stability, and translation. This study aimed to demystify the crosstalk between m6A regulators and the immune microenvironment, providing a potential therapeutic target for patients with hepatocellular carcinoma (HCC). MethodsTotals of 371 HCC and 50 normal patients were included in this study. GSE121248 and GSE40367 datasets were used to validate the expression of HNRNPC. The R package "ConsensusClusterPlus" was performed to screen consensus clustering types based on the expression of m6A regulators in HCC. The R package "pheatmap", "immunedeconv", "survival", "survminer" and "RMS" were applied to investigate the expression, immunity, overall survival, and clinical application in different clusters and expression groups. Comprehensive analysis of HNRNPC in pan-cancer was conducted by TIMER2 database. Besides, HNRNPC mRNA and protein expression were verified by qRT-PCR and immunohistochemistry analysis. ResultsMost of m6A regulators were over-expressed excerpt for ZC3H13 in HCC. Three independent clusters were screened based on m6A regulators expression, and the cluster 2 had a favorable prognosis in HCC. Then, the cluster 2 was positively expression in macrophage, hematopoietic stem cell, endothelial cell, and stroma score, while negatively in T cell CD4(+) memory and mast cell. We identified HNRNPC was an independent prognostic factor in HCC, and nomogram performed superior application value for clinical decision making. Moreover, PD-L1 was significantly up-regulated in HCC tissues, cluster 1, and cluster 3, and we found PD-L1 expression was positively correlated with HNRNPC. Patients with HCC in high-expression groups was associated with tumor-promoting cells. Besides, HNRNPC was correlated with prognosis, TMB, and immune checkpoints in cancers. Particularly, the experiments confirmed that HNRNPC was positively expression in HCC cells and tissues. ConclusionThe m6A regulators play irreplaceable roles in prognosis and immune infiltration in HCC, and the relationship of HNRNPC and PD-L1 possesses a promising direction for therapeutic targets of immunotherapy response. Exploration of m6A regulators pattern could be build the prognostic stratification of individual patients and move toward to personalized treatment.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] N6-methyladenosine RNA modification in PD-1/PD-L1: Novel implications for immunotherapy
    Luo, Ping
    Li, Shiqi
    Long, Xinghua
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (03):
  • [2] RNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape and Clinical Significance
    Zhao, Hua
    Zhou, Qiujun
    Shi, Chengwei
    Shao, Yaojian
    Ni, Junjie
    Lou, Jianying
    Wei, Shenyu
    MEDICAL SCIENCE MONITOR, 2021, 27
  • [3] N6-methyladenosine participates in mouse hippocampus neurodegeneration via PD-1/PD-L1 pathway
    Hu, Wen
    Xie, Hongbo
    Zeng, Yubing
    Pei, Pei
    Zhan, Xiaojun
    Wang, Shan
    Wang, Zhenlin
    FRONTIERS IN NEUROSCIENCE, 2023, 17
  • [4] Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma
    Yu, Zhong Lin
    Zhu, Zheng Ming
    BIOENGINEERED, 2021, 12 (01) : 1708 - 1724
  • [5] N6-methyladenosine (m6A) modification in hepatocellular carcinoma
    Ma, Hehua
    Hong, Yuxin
    Xu, Zhenzhen
    Weng, Zuyi
    Yang, Yuanxun
    Jin, Dandan
    Chen, Zhiyou
    Yue, Jing
    Zhou, Xuan
    Xu, Zhi
    Fei, Fei
    Li, Juan
    Song, Wei
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 173
  • [6] N6-methyladenosine associated prognostic model in hepatocellular carcinoma
    Huang, Hanchun
    Bai, Yi
    Lu, Xin
    Xu, Yiyao
    Zhao, Haitao
    Sang, Xinting
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (10)
  • [7] New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy
    Li, Mengran
    Tian, Hu
    Zhuang, Yanshuang
    Zhang, Zili
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [8] RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells
    Tsuruta, Nobuhiro
    Tsuchihashi, Kenji
    Ohmura, Hirofumi
    Yamaguchi, Kyoko
    Ito, Mamoru
    Ariyama, Hiroshi
    Kusaba, Hitoshi
    Akashi, Koichi
    Baba, Eishi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 530 (01) : 235 - 239
  • [9] Reserpine, a novel N6-methyladenosine regulator, reverses Lenvatinib resistance in hepatocellular carcinoma
    Zhao, Lei
    Ma, Heyao
    Jiang, Yuhui
    Li, Yingying
    Guo, Ning
    Chen, Yu
    Jiang, Xiaowen
    Zhao, Yunpeng
    Yang, Jingjing
    Liu, Yifei
    Wen, Kaishu
    Wang, Lihui
    Jian, Lingyan
    Fan, Xinyu
    PHYTOMEDICINE, 2024, 135
  • [10] PD-L1 expression is regulated by RNA N6-methyladenosine demethylase FTO in colon cancer cells
    Tsuchihashi, Kenji
    Tsuruta, Nobuhiro
    Ohmura, Hirofumi
    Yamaguchi, Kyoko
    Ito, Mamoru
    Tanoue, Kenro
    Isobe, Taichi
    Ariyama, Hiroshi
    Kusaba, Hitoshi
    Akashi, Koichi
    Baba, Eishi
    CANCER SCIENCE, 2022, 113 : 1331 - 1331